Platinum
ASSET MANAGEMENT

FACSIMILE COVER PAGE

To:	Company Announcements	From:	Matthew Githens
Fax:	1300 135 638	Fax #:	02 9254 5590
Company:	ASX	Tel #:	02 9255 7576

Subject:	Substantial Shareholding Disclosure – Antisense Therapeutics Ltd		
Sent:	22 September 2020	Pages:	3 (including cover)

Email:	compliance@platinum.com.au	Website:	www.platinum.com.au

Please find attached the reporting form 605 required under Corporations Act 2001 Section 671B.

I would be grateful if you could confirm receipt to my email address: compliance@platinum.com.au

Kind regards,

Matthew Githens
Chief Risk and Compliance Officer

Platinum Investment Management Limited
Level 8, 7 Macquarie Place, Sydney, NSW 2000

Platinum Investment Management Limited ABN 25 063 565 006 AFSL 221935 trading as Platinum Asset Management ("Platinum")

This facsimile is intended solely for the named addressee(s) and may contain confidential or privileged information. If you are not the intended addressee(s), any use, disclosure or copying of the information contained in this facsimile is unauthorised and prohibited. Please notify the sender immediately and destroy this copy.

Any personal information in this facsimile must be handled in accordance with the Privacy Act 1988 (Cth).

Platinum is a member of the Platinum Group of companies.

Form 605

Corporations Act 2001
Section 671B

Notice of ceasing to be a substantial holder

To Company Name/Scheme: Antisense Therapeutics Limited

ACN/ARSN: 095 060 745

1. Details of substantial holder(1)

Name: Platinum Investment Management Limited

ACN/ARSN (if applicable): 063 565 006

The holder ceased to be a substantial holder on: 21 / 09 / 20

The previous notice was given to the company on: 23 / 12 / 19

The previous notice was dated: 19 / 12 / 19

2. Changes in relevant interests

Particulars of each change in, or change in the nature of, a relevant interest (2) of the substantial holder or an associate (3) in voting securities of the company or scheme, since the substantial holder was last required to give a substantial holding notice to the company or scheme are as follows:

Date of change	Person whose relevant interest changed	Nature of change (4)	Consideration given in relation to change(5)	Class (6) and number of securities affected	Person's votes affected
30/12/2019	Platinum Investment Management Ltd	Acquisition of Shares	$113,680.00	ORD 1,421,000	1,421,000
21/09/2020	Platinum Investment Management Ltd	Disposal of Shares	$76,191.65	ORD 634,681	634,681

3. Changes in association

The persons who have become associates (3) of, ceased to be associates of, or have changed the nature of their association (7) with, the substantial holder in relation to voting interests in the company or scheme are as follows:

Name and ACN/ARSN (if applicable)	Nature of association

4. Addresses

The addresses of persons named in this form are as follows:

Name	Address
Platinum Investment Management Limited	Level 8, 7 Macquarie Place, Sydney NSW 2000

Signature

print name: Matthew Githens capacity: Chief Risk and Compliance Officer

sign here:  date: 22 / 09 / 2020

DIRECTIONS

(1) If there are a number of substantial holders with similar or related relevant interests (eg. a corporation and its related corporations, or the manager and trustee of an equity trust), the names could be included in an annexure to the form. If the relevant interests of a group of persons are essentially similar, they may be referred to throughout the form as a specifically named group if the membership of each group, with the names and addresses of members is clearly set out in paragraph 4 of the form.

(2) See the definition of "relevant interest" in sections 608 and 671B(7) of the Corporations Act 2001.

(3) See the definition of "associate" in section 9 of the Corporations Act 2001.

(4) Include details of:

(a) any relevant agreement or other circumstances because of which the change in relevant interest occurred. If subsection 671B(4) applies, a copy of any document setting out the terms of any relevant agreement, and a statement by the person giving full and accurate details of any contract, scheme or arrangement, must accompany this form, together with a written statement certifying this contract, scheme or arrangement; and

(b) any qualification of the power of a person to exercise, control the exercise of, or influence the exercise of, the voting powers or disposal of the securities to which the relevant interest relates (indicating clearly the particular securities to which the qualification applies).

See the definition of "relevant agreement" in section 9 of the Corporations Act 2001.

(5) Details of the consideration must include any and all benefits, money and other, that any person from whom a relevant interest was acquired has, or may, become entitled to receive in relation to that acquisition. Details must be included even if the benefit is conditional on the happening or not of a contingency. Details must be included of any benefit paid on behalf of the substantial holder or its associate in relation to the acquisitions, even if they are not paid directly to the person from whom the relevant interest was acquired.

(6) The voting shares of a company constitute one class unless divided into separate classes.

(7) Give details, if appropriate, of the present association and any change in that association since the last substantial holding notice.